BioCentury | Oct 10, 2019
Company News

On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

Chronic and genetic diseases company Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Manmeet Soni as CFO and EVP, succeeding Jason Wilson, who will become EVP of operations. Soni was CFO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Scholar Rock...
BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
BioCentury | Sep 21, 2018
Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
BioCentury | Sep 17, 2018
Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
BioCentury | May 10, 2017
Company News

Management tracks

RNA company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced several additions. The biotech named Alan Eisenberg VP of global public policy and government relations; Theresa Heggie SVP and head of Europe and Canada; Peter Smith SVP of...
BioCentury | Sep 9, 2016
Company News

Management tracks

Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN). Sanofi (Euronext:SAN; NYSE:SNY) named Frank Nestle CSO for North America and global head of immunology and inflammation research....
BioCentury | Mar 19, 2016
Company News

Management tracks

Gene editing company CRISPR Therapeutics AG (Basel, Switzerland) named Marc Becker CFO. He was CFO and SVP at rEVO Biologics Inc. (Framingham, Mass.). CRISPR also named Tony Coles, the chairman and CEO of Yumanity Therapeutics...
Items per page:
1 - 10 of 20
BioCentury | Oct 10, 2019
Company News

On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

Chronic and genetic diseases company Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Manmeet Soni as CFO and EVP, succeeding Jason Wilson, who will become EVP of operations. Soni was CFO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Scholar Rock...
BioCentury | Aug 5, 2019
Financial News

Aug. 5 Financial Quick Takes: Biotech tumbles with broader markets; plus Exo, 3-V and more

...Creative Ventures, Longevity Vision Fund, Magnetar Capital, Nautilus Venture Partners, OSF Healthcare, Rising Tide Fund, Sony...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
BioCentury | Sep 21, 2018
Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
BioCentury | Sep 17, 2018
Company News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) had a busy Monday announcing the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp....
BioCentury | Jul 25, 2018
Company News

Management Tracks: Albireo, ObsEva

Pediatric liver disease company Albireo Pharma Inc. (NASDAQ:ALBO) said CMO Paresh Soni will step down. He is succeeded by Patrick Horn, who was SVP of medical and clinical development at Orphan Technologies Ltd. (Rapperswil, Switzerland)....
BioCentury | May 10, 2017
Company News

Management tracks

RNA company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced several additions. The biotech named Alan Eisenberg VP of global public policy and government relations; Theresa Heggie SVP and head of Europe and Canada; Peter Smith SVP of...
BioCentury | Sep 9, 2016
Company News

Management tracks

Oncology company Vaximm AG (Basel, Switzerland) named Matthias Schroff CEO. He was CEO at Mologen AG (Xetra:MGN). Sanofi (Euronext:SAN; NYSE:SNY) named Frank Nestle CSO for North America and global head of immunology and inflammation research....
BioCentury | Mar 19, 2016
Company News

Management tracks

Gene editing company CRISPR Therapeutics AG (Basel, Switzerland) named Marc Becker CFO. He was CFO and SVP at rEVO Biologics Inc. (Framingham, Mass.). CRISPR also named Tony Coles, the chairman and CEO of Yumanity Therapeutics...
Items per page:
1 - 10 of 20